Heart disease is the #1 cause of death in the world today, with heart failure alone costing over $30 billion a year in the U.S.
Myocarditis is one pathway into that broader crisis—and no drug has ever been shown to work in it.
Data from the ARCHER trial now suggest CardiolRx�� could be the first—and may have opened the door to the largest unmet need in cardiology: heart failure.
(NASDAQ: CRDL | TSX: CRDL)
🎥 Watch the full ARCHER Phase II results video: